基于整合网络药理学和实验验证探究九味补血口服液调控Glu/GABA动态平衡改善失眠大鼠睡眠机制的研究
Sleep-improving mechanisms of Jiu Wei Bu Xue Oral Liquid on regulating Glu/GABA balance in insomnia rats based on network pharmacology and experimental verification
-
摘要: 本研究拟通过网络药理学分析、分子对接结合体内实验验证, 探究九味补血口服液对失眠大鼠的睡眠改善机制。利用UPLC-Q-TOF-MS/MS分析结合数据库获取九味补血口服液的化学成分及其候选靶标, 并通过蛋白质互作和网络分析, 筛选九味补血口服液治疗失眠的关键网络靶标和潜在活性成分, 进行生物功能富集及通路分析。再采用分子对接技术对上述关键靶标和活性成分进行结合能力预测; 通过对氯苯丙氨酸(PCPA) 腹腔注射复制大鼠失眠模型, 给予九味补血口服液(2、4、8 mL·kg-1) 干预7天, 开展戊巴比妥钠阈上剂量诱导睡眠实验, 考察九味补血口服液协同助眠作用。检测海马和下丘脑组织中谷氨酸(Glu)、γ-氨基丁酸(GABA) 含量, 比色法检测海马组织中谷氨酸脱羧酶1 (GAD67) 酶活力, qRT-PCR和免疫印迹法检测海马组织中GAD67、γ-氨基丁酸A受体α1 (GABRA1)、γ-氨基丁酸A受体β2 (GABRB2) mRNA和蛋白质表达水平。动物实验经广西壮族自治区中医药研究院实验动物伦理委员会批准(编号2022060802)。结果表明, 通过构建九味补血口服液中药-成分-失眠疾病靶点网络, 获得该品种治疗失眠的16个关键网络靶标和16个潜在活性成分。网络药理学和分子对接分析显示, 白术内酯Ⅲ等16个潜在活性成分与GABRA1、GABRB2蛋白质具有潜在的结合能力。在动物实验验证中, 与失眠大鼠模型组相比, 九味补血口服液显著缩短失眠大鼠睡眠潜伏期, 延长睡眠时长, 并明显提高其海马组织中GAD67酶活力及GABA生成量, 以及GAD67、GABAA受体亚基GABRA1、GABRB2的mRNA和蛋白质表达水平, 而降低下丘脑组织中Glu含量, 最终降低下丘脑和海马中Glu/GABA比值, 保持脑内Glu、GABA动态平衡。综上表明, 九味补血口服液可以改善失眠大鼠症状, 促进海马、下丘脑内Glu和GABA平衡, 减轻失眠后脑内兴奋性神经毒性, 其机制可能与增强GAD67表达及酶活力, 促进海马GABAA受体亚基GABRA1、GABRB2介导的抑制性神经活动有关。Abstract: This study aimed to investigate the mechanism of Jiu Wei Bu Xue Oral Liquid on insomnia rats combining the methods of network pharmacology, molecular docking and experimental verification. UPLC-Q-TOF-MS/MS method and TCMIP, TCMSP databases were used to collect the ingredients and targets of Jiu Wei Bu Xue Oral Liquid. Protein-protein interactions and network analysis were performed to screen the key network targets and putative active ingredients of Jiu Wei Bu Xue Oral Liquid in treatment of insomnia, and then following by biological function and KEGG pathway analysis. Then binding ability for key network targets and putative active ingredients were predicted with molecular docking. The prediction targets were validated in para-chlorophenylalanine (PCPA) induced insomnia rats with administration of Jiu Wei Bu Xue Oral Liquid (2, 4, 8 mL·kg-1) for 7 days. Pentobarbital sodium induced sleeping test were performed to evaluate the synergistic sleep-aiding effect of Jiu Wei Bu Xue Oral Liquid. Then glutamic acid (Glu), γ-aminobutyrate (GABA) content and glutamate decarboxylase 1 (GAD67) activity in hypothalamus or hippocampus were evaluated, and the expressions of GAD67, γ-aminobutyric acid receptor subunit α1 (GABRA1) and γ-aminobutyric acid receptor subunit β2 (GABRB2) in hippocampus were detected by qRT-PCR and Western blot methods. Animal experiments were approved by the Institutional Committee on Animal Care of Guangxi Institute of Chinese Medicine & Pharmaceutical Science (the number of permission: 2022060802). Results showed that 16 key network targets and 16 putative active ingredients were obtained by analyzing the herbs-ingredients-targets network of Jiu Wei Bu Xue Oral Liquid in treatment of insomnia. Network pharmacology and molecular docking all indicated these active ingredients, for example atractylenolide Ⅲ, showed better binding ability with GABRA1 and GABRB2. Animal study indicated that, compared to PCPA-induced insomnia model, Jiu Wei Bu Xue Oral Liquid remarkably shortened the sleeping latency and increased the sleeping duration, increased GAD67 activity and the production of GABA in hippocampus of insomnia rats, as well as the expressions of GAD67, GABRA1 and GABRB2, while decreased Glu content in hypothalamus, leading to decreasing of Glu/GABA ratio and recovery of Glu-GABA balance. These results indicated that Jiu Wei Bu Xue Oral Liquid improved insomnia symptoms and helped maintain the Glu-GABA balance within hypothalamus and hippocampus, and reduced the excitatory neurotoxicity within brain. The mechanism may due to the elevation of GAD67 expression and enzyme activity, and the enhancement of type-A GABA receptor (GABAAR)-mediated neurons inhibition.
下载: